Merck (MRK) Stock Climbs After FDA Greenlight for Revolutionary Cholesterol Medication

Merck (MRK) stock gains after FDA approves Lipfendra, the first oral PCSK9 inhibitor for high cholesterol, priced competitively at $315/month.

The post Merck (MRK) Stock Climbs After FDA Greenlight for Revolutionary Cholesterol Medication appeared first on Blockonomi.